About Phosphatidylinositol transfer protein alpha isoform
Phosphatidylinositol transfer protein alpha isoform (PITPNA) is a protein
from Homo sapiens identified by UniProt accession
Q00169, 270 residues long.
MolForge cross-references it against 0 known binders and
153 disease associations.
Target properties
| Protein name | Phosphatidylinositol transfer protein alpha isoform |
|---|
| UniProt accession | Q00169 |
|---|
| Gene | PITPNA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 270 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (153)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- mean platelet volume · score 0.29
- thyroid gland adenocarcinoma · score 0.18
- Abnormal central motor function · score 0.16
- alcohol consumption measurement · score 0.15
- hepatocellular carcinoma · score 0.10
- squamous cell lung carcinoma · score 0.10
- non-small cell lung carcinoma · score 0.08
- triple-negative breast cancer · score 0.07
- type 2 diabetes mellitus · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q00169-F1 | alphafold | PREDICTED | 95.39 | — |
Amino-acid sequence (270 residues)
MVLLKEYRVI LPVSVDEYQV GQLYSVAEAS KNETGGGEGV EVLVNEPYEK DGEKGQYTHK IYHLQSKVPT FVRMLAPEGA LNIHEKAWNA YPYCRTVITN EYMKEDFLIK IETWHKPDLG TQENVHKLEP EAWKHVEAVY IDIADRSQVL SKDYKAEEDP AKFKSIKTGR GPLGPNWKQE LVNQKDCPYM CAYKLVTVKF KWWGLQNKVE NFIHKQERRL FTNFHRQLFC WLDKWVDLTM DDIRRMEEET KRQLDEMRQK DPVKGMTADD
Explore Phosphatidylinositol transfer protein alpha isoform with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets